These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15479487)

  • 1. Highlights from the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA. June 2004.
    Lee D; Price N; Reddy K
    Clin Prostate Cancer; 2004 Sep; 3(2):73-6. PubMed ID: 15479487
    [No Abstract]   [Full Text] [Related]  

  • 2. The endothelin-1 antagonist, atrasentan, improves time to progression and quality of life in hormone-refractory prostate cancer.
    Fisher M
    Clin Prostate Cancer; 2002 Sep; 1(2):79-80. PubMed ID: 15046697
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer chemotherapy: emerging from the shadows.
    Roth BJ
    J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529
    [No Abstract]   [Full Text] [Related]  

  • 4. Activity of epothilone B analogues ixabepilone and patupilone in hormone-refractory prostate cancer.
    Lee D
    Clin Prostate Cancer; 2004 Sep; 3(2):80-2. PubMed ID: 15479489
    [No Abstract]   [Full Text] [Related]  

  • 5. Highlights from 40th Annual Meeting of the American Society of Clinical Oncology New Orleans, LA, June 2004.
    Lee D
    Clin Colorectal Cancer; 2004 Sep; 4(3):154-8. PubMed ID: 15377398
    [No Abstract]   [Full Text] [Related]  

  • 6. Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer.
    Price N
    Clin Prostate Cancer; 2004 Sep; 3(2):77-9. PubMed ID: 15479488
    [No Abstract]   [Full Text] [Related]  

  • 7. Appendix 1: Cancer of the Prostate: eUpdate published online 28 September 2017 (http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate).
    ESMO Guidelines Committee
    Ann Oncol; 2018 Oct; 29(Suppl 4):iv256. PubMed ID: 30285212
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
    Taneja SS
    J Urol; 2014 Mar; 191(3):656. PubMed ID: 24522033
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapies in development for castrate-resistant prostate cancer.
    Harzstark AL; Ryan CJ
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):259-68. PubMed ID: 18279066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rebuttal from authors re: Joaquim Bellmunt. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol 2009;55:1310-2.
    Italiano A; Fizazi K
    Eur Urol; 2009 Jun; 55(6):1313-4. PubMed ID: 18849106
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.
    Berry WR; Hathorn JW; Dakhil SR; Loesch DM; Jackson DV; Gregurich MA; Newcomb-Fernandez JK; Asmar L
    Clin Prostate Cancer; 2004 Sep; 3(2):104-11. PubMed ID: 15479494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current strategies of intermittent hormone therapy in prostate cancer].
    Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
    Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail?
    Bellmunt J
    Eur Urol; 2009 Jun; 55(6):1310-2. PubMed ID: 18778888
    [No Abstract]   [Full Text] [Related]  

  • 14. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
    DeGrendele H
    Clin Prostate Cancer; 2003 Mar; 1(4):212-4. PubMed ID: 15040878
    [No Abstract]   [Full Text] [Related]  

  • 15. Highlights from the 29th European Society for Medical Oncology Congress: Vienna, Austria, October 29 through November 2, 2004.
    Price N
    Clin Prostate Cancer; 2004 Dec; 3(3):136-40. PubMed ID: 15636678
    [No Abstract]   [Full Text] [Related]  

  • 16. Cabazitaxel in prostate cancer: stretching a string.
    Dorff TB; Quinn DI
    Lancet; 2010 Oct; 376(9747):1119-20. PubMed ID: 20888974
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
    Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy of hormone refractory prostate carcinoma].
    Wirth MP; Nippgen J
    Urologe A; 2003 Nov; 42(11):1453-60. PubMed ID: 14624343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
    Jilani A; George E; Adler AI
    Lancet Oncol; 2012 Jun; 13(6):573-4. PubMed ID: 22833888
    [No Abstract]   [Full Text] [Related]  

  • 20. Highlights from the 41st Annual Meeting of the American Society of Clinical Oncology, May 2005, and the 2005 American Society of Clinical Oncology Prostate Cancer Symposium, February 2005, Orlando, Florida.
    Reddy GK; Tyagi P
    Clin Prostate Cancer; 2005 Jun; 4(1):7-14. PubMed ID: 15992456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.